baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BioCardia/ US09060U6064 /

25/09/2024 21:59:50	Chg. +0.16	Volume	Bid-	Ask-	High	Low
2.58USD	+6.39%	293 Turnover: 739.94	-Bid Size: -	-Ask Size: -	2.58	2.42

GlobeNewswire 30/08 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasda...

GlobeNewswire 29/08 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire 21/08 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analys...

GlobeNewswire 13/08 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

GlobeNewswire 07/08 BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

GlobeNewswire 30/07 BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire 25/07 Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of ...

GlobeNewswire 17/07 BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter ...

GlobeNewswire 08/07 CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatm...

GlobeNewswire 07/06 BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to ...

GlobeNewswire 21/05 BioCardia Announces Reverse Stock Split

GlobeNewswire 14/05 BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

GlobeNewswire 09/05 BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

GlobeNewswire 01/05 BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in...

GlobeNewswire 25/04 BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Isch...

GlobeNewswire 27/03 BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

GlobeNewswire 20/03 BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

GlobeNewswire 13/03 BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

GlobeNewswire 12/03 BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart ...

GlobeNewswire 04/03 BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial,...

GlobeNewswire 08/02 BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved ...

GlobeNewswire 03/01 BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Share...

GlobeNewswire 19/12/2023 BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchym...

GlobeNewswire 18/12/2023 BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical ...

GlobeNewswire 29/11/2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemi...

BioCardia/ US09060U6064 /

If you wish to receive reply to your feedback, please provide your email address.